<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335146">
  <stage>Registered</stage>
  <submitdate>9/02/2010</submitdate>
  <approvaldate>15/04/2010</approvaldate>
  <actrnumber>ACTRN12610000300077</actrnumber>
  <trial_identification>
    <studytitle>Accuracy of a Positron Emission Tomography (PET) and Beta Probe in the Staging of Ductal Carcinoma In Situ &amp; Invasive Ductal Cancer of the Breast.</studytitle>
    <scientifictitle>Accuracy of a Positron Emission Tomography (PET) and Beta Probe in the Staging of Ductal Carcinoma In Situ &amp; Invasive Ductal Cancer of the Breast.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This multidisciplinary one year study will consist of a cohort of 60 patients who have ductal carcinoma in situ (DCIS) or invasive breast cancer, as confirmed by biopsy.  Thirty minutes prior to theatre, the patient is injected with 150MBq of f18flurodeoxyglucose (FDG) through a cannula placed in the contra-lateral arm to the breast of interest.  Once the specimen has been surgically removed and orientated, the Surgeon will use the beta probe to record counts within the surgical cavity, recording the same orientated surfaces as for the excised tissue.  The excised tissue will be orientated and the counts recorded for each of the six surfaces (superior, inferior, medial, lateral, superficial, deep) using the beta probe.  The gamma probe will then be used over the excised tissue to verify the sample contains FDG positive tissue. In this initial study there would be no action taken on these findings.</interventions>
    <comparator>NA</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Accuracy of the PET probe. Counts per second in areas where the probe has detected FDG will be recorded on the data collection sheet. This will be compared to the histology results, and in particular the clearance of the surgical margins and where there was not clearance, distance between the DCIS of invasive tissue and the margin/s.</outcome>
      <timepoint>Review all data after one year worth of recruitment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Confirm probe protocol. A good sensitivity and specificity based on the primary outcome confirms the protocol (injection dose and timing) is correct.</outcome>
      <timepoint>Review all data after one year worth of recruitment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.	Patient with newly diagnosed DCIS or invasive carcinoma of the breast;
2.	Planned to undergo surgical wide local excision;
3.	Able to provide informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.	Planned mastectomy or neoadjuvant therapy;
2.	Uncontrolled diabetes mellitus;
3.	Pregnant at the time of surgery;
4.	Unable to provide informed consent.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>30/04/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Curtin University</primarysponsorname>
    <primarysponsoraddress>GPO Box U1987
Perth WA 6845</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Cancer Australia</fundingname>
      <fundingaddress>PO Box 1201
Dickson
Canberra
ACT 2602</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>National Breast Cancer Foundation</fundingname>
      <fundingaddress>GPO Box 4126 SYDNEY NSW 2001</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cancer Council of WA</fundingname>
      <fundingaddress>46 Ventnor Avenue
West Perth WA 6005</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is examining if the use of a PET probe during surgery for DCIS or breast cancer can accurately determine if all of the cancer cells have been removed. Currently 20% of patients require a second operation due to potential remaining cancer cells in the breast. Identification of these cells at the time of the first operation may reduce the number of women requiring second
operations. This will have an impact on the patient (time &amp; distress) and the health care system.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Mount Ethics Committee</ethicname>
      <ethicaddress>Mount Hospital
140 Mounts Bay Road
Perth WA 6000</ethicaddress>
      <ethicapprovaldate>14/10/2008</ethicapprovaldate>
      <hrec>EC28.1</hrec>
      <ethicsubmitdate>8/05/2008</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Curtin University Human Research Ethics Committee</ethicname>
      <ethicaddress>Curtin University of Technology
GPO Box U1987
Perth WA 6845</ethicaddress>
      <ethicapprovaldate>8/08/2006</ethicapprovaldate>
      <hrec>HR 58/2006</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kerryn Butler-Henderson</name>
      <address>School of Public Health
Curtin University
GPO Box U1987
Perth WA 6845</address>
      <phone>+618 9266 7531</phone>
      <fax />
      <email>K.Butler-Henderson@curtin.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kerryn Butler-Henderson</name>
      <address>School of Public Health
Curtin University
GPO Box U1987
Perth WA 6845</address>
      <phone>+618 9266 7531</phone>
      <fax />
      <email>K.Butler-Henderson@curtin.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kerryn Butler-Henderson</name>
      <address>School of Public Health
Curtin University
GPO Box U1987
Perth WA 6845</address>
      <phone>+618 9266 7531</phone>
      <fax />
      <email>K.Butler-Henderson@curtin.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>